The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

[1]  J. Chiang,et al.  G‐protein‐coupled bile acid receptor plays a key role in bile acid metabolism and fasting‐induced hepatic steatosis in mice , 2017, Hepatology.

[2]  P. Gervasi,et al.  Effect of HFD/STZ on expression of genes involved in lipid, cholesterol and glucose metabolism in rats. , 2016, Life sciences.

[3]  C. Brocker,et al.  Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans[S] , 2016, Journal of Lipid Research.

[4]  A. Zou,et al.  Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells , 2016, BioMed research international.

[5]  B. Stieger,et al.  Recent advances in understanding hepatic drug transport , 2016, F1000Research.

[6]  A. Moschetta,et al.  Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders. , 2016, Journal of medicinal chemistry.

[7]  J. Chiang,et al.  Cholesterol 7α-hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis[S] , 2016, Journal of Lipid Research.

[8]  P. Dawson,et al.  Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet–fed mice , 2016, Science Translational Medicine.

[9]  D. Kuzmenko,et al.  Role of ceramide in apoptosis and development of insulin resistance , 2016, Biochemistry (Moscow).

[10]  L. Iuliano,et al.  Effects of dietary fatty acids and cholesterol excess on liver injury: A lipidomic approach , 2016, Redox biology.

[11]  Yuhuan Luo,et al.  Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease* , 2016, The Journal of Biological Chemistry.

[12]  F. Lu,et al.  Effects of different diets on intestinal microbiota and nonalcoholic fatty liver disease development. , 2016, World journal of gastroenterology.

[13]  Lanjuan Li,et al.  Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease , 2016, Scientific Reports.

[14]  Min Zhang,et al.  Fatty liver diseases, bile acids, and FXR , 2016, Acta pharmaceutica Sinica. B.

[15]  E. Tsochatzis,et al.  The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). , 2016, Metabolism: clinical and experimental.

[16]  Dustin E. Schones,et al.  Vertical sleeve gastrectomy activates GPBAR‐1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice , 2016, Hepatology.

[17]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[18]  H. Schiöth,et al.  Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, bile acid and drug metabolism in human hepatocytes. , 2016, Life Science.

[19]  E. Elinav,et al.  Non-alcoholic fatty liver and the gut microbiota , 2016, Molecular metabolism.

[20]  H. Ebrahimi,et al.  New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article , 2016, Middle East journal of digestive diseases.

[21]  J. Oben,et al.  A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence , 2016, International journal of molecular sciences.

[22]  E. Comelli,et al.  Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease , 2016, PloS one.

[23]  J. Heeren,et al.  Metabolic interplay between white, beige, brown adipocytes and the liver. , 2016, Journal of hepatology.

[24]  Prasad Bhate,et al.  An Open-label Randomized Control Study to Compare the Efficacy of Vitamin E versus Ursodeoxycholic Acid in Nondiabetic and Noncirrhotic Indian NAFLD Patients , 2016, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[25]  Wei Jia,et al.  Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics , 2016, International journal of molecular sciences.

[26]  C. Still,et al.  Bile Acids, FXR, and Metabolic Effects of Bariatric Surgery , 2016, Journal of obesity.

[27]  H. Yoshiji,et al.  Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis , 2016, Journal of Gastroenterology.

[28]  K. Bambha,et al.  Bile acid receptors and nonalcoholic fatty liver disease. , 2015, World journal of hepatology.

[29]  Zhiqiang Liu,et al.  Co-Administration of Cholesterol-Lowering Probiotics and Anthraquinone from Cassia obtusifolia L. Ameliorate Non-Alcoholic Fatty Liver , 2015, PloS one.

[30]  A. Sanyal,et al.  Bile acids: emerging role in management of liver diseases , 2015, Hepatology International.

[31]  A. Sanyal,et al.  Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease , 2015, Seminars in Liver Disease.

[32]  K. Brouwer,et al.  Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis , 2015, Digestive Diseases and Sciences.

[33]  N. Chavez-Tapia,et al.  The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease. , 2015, Annals of hepatology.

[34]  B. Stieger,et al.  Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[35]  D. Rajpal,et al.  Effect of Roux-en-Y Gastric Bypass Surgery on Bile Acid Metabolism in Normal and Obese Diabetic Rats , 2015, PloS one.

[36]  B. Neuschwander‐Tetri,et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.

[37]  P. Hylemon,et al.  Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism , 2015, Acta pharmaceutica Sinica. B.

[38]  R. Haeusler,et al.  Temporal changes in bile acid levels and 12α-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes , 2015, International Journal of Obesity.

[39]  I. Albert,et al.  Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. , 2015, The Journal of clinical investigation.

[40]  Yan Lu,et al.  Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis , 2014, Acta Pharmacologica Sinica.

[41]  R. Safadi,et al.  The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[42]  Su Yeon Lee,et al.  Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice , 2014, Experimental & Molecular Medicine.

[43]  S. Pandol,et al.  Vitamin D deficiency promotes nonalcoholic steatohepatitis through impaired enterohepatic circulation in animal model. , 2014, American journal of physiology. Gastrointestinal and liver physiology.

[44]  R. Seeley,et al.  The role of small heterodimer partner in nonalcoholic fatty liver disease improvement after sleeve gastrectomy in mice , 2014, Obesity.

[45]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. , 2014, Hepatology.

[46]  M. Arrese,et al.  Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion , 2014, Journal of Physiology and Biochemistry.

[47]  O. Tirosh,et al.  L-arginine conjugates of bile acids-a possible treatment for non-alcoholic fatty liver disease , 2014, Lipids in Health and Disease.

[48]  L. Schiavon,et al.  Adiponectin: A multitasking player in the field of liver diseases. , 2014, Diabetes & metabolism.

[49]  V. Tremaroli,et al.  FXR is a molecular target for the effects of vertical sleeve gastrectomy , 2014, Nature.

[50]  Y. Yamori,et al.  A Possible Role of Chenodeoxycholic Acid and Glycine-Conjugated Bile Acids in Fibrotic Steatohepatitis in a Dietary Rat Model , 2014, Digestive Diseases and Sciences.

[51]  Yanqiao Zhang,et al.  Bile acid receptors in non-alcoholic fatty liver disease. , 2013, Biochemical pharmacology.

[52]  S. Mudaliar,et al.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. , 2013, Gastroenterology.

[53]  J. Alves,et al.  Cirrhosis, bile acids and gut microbiota , 2013, Gut microbes.

[54]  M. Bohlooly-y,et al.  Ageing Fxr Deficient Mice Develop Increased Energy Expenditure, Improved Glucose Control and Liver Damage Resembling NASH , 2013, PloS one.

[55]  P. Scherer,et al.  An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. , 2013, Cell metabolism.

[56]  G. Combs,et al.  Fatty liver accompanies an increase in lactobacillus species in the hind gut of C57BL/6 mice fed a high-fat diet. , 2013, The Journal of nutrition.

[57]  N. Araníbar,et al.  Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. , 2013, Toxicology and applied pharmacology.

[58]  S. Friedman,et al.  Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid‐induced liver injury in superobese patients with nonalcoholic steatohepatitis , 2013, Hepatology.

[59]  L. Adorini,et al.  Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease* , 2013, The Journal of Biological Chemistry.

[60]  E. Comelli,et al.  Intestinal microbiota in patients with nonalcoholic fatty liver disease , 2013, Hepatology.

[61]  Lixin Zhu,et al.  Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH , 2013, Hepatology.

[62]  T. Nakajima,et al.  SIMPLE AND RAPID QUANTITATION OF 21 BILE ACIDS IN RAT SERUM AND LIVER BY UPLC-MS-MS: EFFECT OF HIGH FAT DIET ON GLYCINE CONJUGATES OF RAT BILE ACIDS , 2013, Nagoya journal of medical science.

[63]  R. Loomba,et al.  Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non‐alcoholic fatty liver disease , 2012, Alimentary pharmacology & therapeutics.

[64]  J. Chiang,et al.  Mechanism of tissue‐specific farnesoid X receptor in suppressing the expression of genes in bile‐acid synthesis in mice , 2012, Hepatology.

[65]  N. Tanaka,et al.  Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis , 2012, Hepatology.

[66]  Ann M. Thomas,et al.  Farnesoid X Receptor Induces Murine Scavenger Receptor Class B Type I via Intron Binding , 2012, PloS one.

[67]  S. Spiegel,et al.  Conjugated bile acids activate the sphingosine‐1‐phosphate receptor 2 in primary rodent hepatocytes , 2012, Hepatology.

[68]  B. M. Forman,et al.  The G‐Protein‐coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light‐chain enhancer of activated B cells (NF‐κB) in mice , 2011, Hepatology.

[69]  A. S. Andreasen,et al.  Type 2 Diabetes Is Associated with Altered NF-κB DNA Binding Activity, JNK Phosphorylation, and AMPK Phosphorylation in Skeletal Muscle after LPS , 2011, Front. Nutr..

[70]  M. Orešič,et al.  Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity , 2011, Diabetes.

[71]  J. Auwerx,et al.  Lowering Bile Acid Pool Size with a Synthetic Farnesoid X Receptor (FXR) Agonist Induces Obesity and Diabetes through Reduced Energy Expenditure* , 2011, The Journal of Biological Chemistry.

[72]  Yuan An,et al.  Soluble FGFR4 extracellular domain inhibits FGF19-induced activation of FGFR4 signaling and prevents nonalcoholic fatty liver disease. , 2011, Biochemical and biophysical research communications.

[73]  J. Dufour,et al.  UDCA for NASH: end of the story? , 2011, Journal of hepatology.

[74]  S. Kalhan,et al.  Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis , 2011, European journal of gastroenterology & hepatology.

[75]  V. de Lédinghen,et al.  A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. , 2011, Journal of hepatology.

[76]  M. Milburn,et al.  Plasma metabolomic profile in nonalcoholic fatty liver disease. , 2011, Metabolism: clinical and experimental.

[77]  B. Stieger,et al.  Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice , 2010, Biological chemistry.

[78]  Jouhyun Jeon,et al.  Changes in Hepatic Gene Expression upon Oral Administration of Taurine-Conjugated Ursodeoxycholic Acid in ob/ob Mice , 2010, PloS one.

[79]  L. Adorini,et al.  Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist , 2010, Molecular Pharmacology.

[80]  T. Berg,et al.  High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial , 2010, Hepatology.

[81]  J. Dufour,et al.  Significance of serum adiponectin levels in patients with chronic liver disease , 2010, Clinical science.

[82]  Ann M. Thomas,et al.  Genome‐wide tissue‐specific farnesoid X receptor binding in mouse liver and intestine , 2010, Hepatology.

[83]  K. Kotoh,et al.  NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease , 2010, Lipids in Health and Disease.

[84]  A. Nederveen,et al.  The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[85]  J. Auwerx,et al.  TGR5-mediated bile acid sensing controls glucose homeostasis. , 2009, Cell metabolism.

[86]  J. Holst,et al.  Serum Bile Acids Are Higher in Humans With Prior Gastric Bypass: Potential Contribution to Improved Glucose and Lipid Metabolism , 2009, Obesity.

[87]  Songwen Zhang,et al.  Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. , 2009, Journal of hepatology.

[88]  S. Strom,et al.  Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α‐hydroxylase gene expression , 2009, Hepatology.

[89]  O. Tawfik,et al.  Farnesoid X Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat Diet , 2009, Journal of Pharmacology and Experimental Therapeutics.

[90]  J. Bernheim,et al.  Treatment of preestablished diet-induced fatty liver by oral fatty acid–bile acid conjugates in rodents , 2008, European journal of gastroenterology & hepatology.

[91]  S. Brand,et al.  Free fatty acids sensitize hepatocytes to bile acid-induced apoptosis. , 2008, Biochemical and biophysical research communications.

[92]  H. Cortez‐Pinto,et al.  Bile acid levels are increased in the liver of patients with steatohepatitis , 2008, European journal of gastroenterology & hepatology.

[93]  S. Kliewer,et al.  Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine Published, JLR Papers in Press, August 24, 2007. , 2007, Journal of Lipid Research.

[94]  W. Mckeehan,et al.  FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver , 2007, Diabetes.

[95]  B. Brewer,et al.  Effects of FXR in foam-cell formation and atherosclerosis development. , 2006, Biochimica et biophysica acta.

[96]  J. Dufour,et al.  Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[97]  P. Edwards,et al.  FXR Deficiency Causes Reduced Atherosclerosis in Ldlr−/− Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[98]  Folkert Kuipers,et al.  The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice* , 2006, Journal of Biological Chemistry.

[99]  Ke Ma,et al.  Farnesoid X receptor is essential for normal glucose homeostasis. , 2006, The Journal of clinical investigation.

[100]  T. Willson,et al.  Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[101]  S. Kliewer,et al.  Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. , 2005, Cell metabolism.

[102]  Guo‐Liang Wang,et al.  Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. , 2005, World journal of gastroenterology.

[103]  R. Savkur,et al.  Regulation of carbohydrate metabolism by the farnesoid X receptor. , 2005, Endocrinology.

[104]  P. Dawson,et al.  The Heteromeric Organic Solute Transporter α-β, Ostα-Ostβ, Is an Ileal Basolateral Bile Acid Transporter* , 2005, Journal of Biological Chemistry.

[105]  Sander M Houten,et al.  Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. , 2004, The Journal of clinical investigation.

[106]  L. Burgart,et al.  Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial , 2004, Hepatology.

[107]  S. Kliewer,et al.  Complementary Roles of Farnesoid X Receptor, Pregnane X Receptor, and Constitutive Androstane Receptor in Protection against Bile Acid Toxicity* , 2003, Journal of Biological Chemistry.

[108]  H. Fujii,et al.  Bile Acids Enhance Low Density Lipoprotein Receptor Gene Expression via a MAPK Cascade-mediated Stabilization of mRNA* , 2002, The Journal of Biological Chemistry.

[109]  S. Wright,et al.  Lithocholic Acid Decreases Expression of Bile Salt Export Pump through Farnesoid X Receptor Antagonist Activity* , 2002, The Journal of Biological Chemistry.

[110]  M. Haussler,et al.  Vitamin D Receptor As an Intestinal Bile Acid Sensor , 2002, Science.

[111]  D. Moore,et al.  Bile acids regulate the ontogenic expression of ileal bile acid binding protein in the rat via the farnesoid X receptor. , 2002, Gastroenterology.

[112]  J. Dallongeville,et al.  Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. , 2002, The Journal of clinical investigation.

[113]  Paul T Tarr,et al.  Regulation of Multidrug Resistance-associated Protein 2 (ABCC2) by the Nuclear Receptors Pregnane X Receptor, Farnesoid X-activated Receptor, and Constitutive Androstane Receptor* , 2002, The Journal of Biological Chemistry.

[114]  R. Lawn,et al.  ABCA1. The gatekeeper for eliminating excess tissue cholesterol. , 2001, Journal of lipid research.

[115]  Masahiro Tohkin,et al.  Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis , 2000, Cell.

[116]  T. A. Kerr,et al.  Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. , 2000, Molecular cell.

[117]  D. Mangelsdorf,et al.  Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. , 2000, Science.

[118]  L. Moore,et al.  A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. , 2000, Molecular cell.

[119]  L. Moore,et al.  Identification of a chemical tool for the orphan nuclear receptor FXR. , 2000, Journal of medicinal chemistry.

[120]  D. Keppler,et al.  Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. , 1999, Biochimica et biophysica acta.

[121]  M. Makishima,et al.  Identification of a nuclear receptor for bile acids. , 1999, Science.

[122]  Jasmine Chen,et al.  Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. , 1999, Molecular cell.

[123]  R. Draenert,et al.  Effects of sodium selenite on deoxycholic acid-induced hyperproliferation of human colonic mucosa in short-term culture. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[124]  C. Day,et al.  Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.

[125]  P. Dawson,et al.  Cloning and molecular characterization of the ontogeny of a rat ileal sodium-dependent bile acid transporter. , 1995, The Journal of clinical investigation.

[126]  P. Meier,et al.  Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. , 1994, The Journal of clinical investigation.

[127]  P. Dawson,et al.  Expression cloning and characterization of the hamster ileal sodium-dependent bile acid transporter. , 1994, The Journal of biological chemistry.

[128]  D. Russell,et al.  Bile acid biosynthesis. , 1992, Biochemistry.

[129]  R. Diasio,et al.  Purification and characterization of bile acid-CoA:amino acid N-acyltransferase from human liver. , 1991, The Journal of biological chemistry.

[130]  P. Killenberg,et al.  Purification and characterization of bile acid-CoA:amino acid N-acyltransferase from rat liver. , 1978, The Journal of biological chemistry.

[131]  Hofmann Af.  THE FUNCTION OF BILE SALTS IN FAT ABSORPTION. THE SOLVENT PROPERTIES OF DILUTE MICELLAR SOLUTIONS OF CONJUGATED BILE SALTS , 1963 .

[132]  Yunpeng Qi,et al.  Bile acid signaling in lipid metabolism: metabolomic and lipidomic analysis of lipid and bile acid markers linked to anti-obesity and anti-diabetes in mice. , 2015, Biochimica et biophysica acta.

[133]  K. Faber,et al.  University of Groningen Metformin Protects Rat Hepatocytes against Bile Acid-Induced Apoptosis , 2013 .

[134]  S. Sookoian,et al.  Effects of bile acid sequestration on hepatic steatosis in obese mice. , 2013, Annals of hepatology.

[135]  D. Rajpal,et al.  Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. , 2012, American journal of physiology. Endocrinology and metabolism.

[136]  A. Anisfeld,et al.  BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. , 2002, Journal of lipid research.

[137]  F. Suchy,et al.  Removal of the bile acid pool upregulates cholesterol 7alpha-hydroxylase by deactivating FXR in rabbits. , 2002, Journal of lipid research.

[138]  A. von Eckardstein,et al.  High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[139]  M. Noshiro,et al.  Insulin is a dominant suppressor of sterol 12 alpha-hydroxylase P450 (CYP8B) expression in rat liver: possible role of insulin in circadian rhythm of CYP8B. , 2000, Journal of biochemistry.

[140]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.

[141]  R. Dowling.  The enterohepatic circulation of bile acids as they relate to lipid disorders. , 1973, Journal of clinical pathology. Supplement.